Recombinant human hemoglobins designed for gene therapy of sickle cell disease.
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Two human hemoglobins designed to inhibit the polymerization of sickle hemoglobin (Hb S; alpha 2 beta S2) have been produced. Mutations that disrupt the ability of Hb S to form polymers were introduced into the normal human beta-globin gene by site-specific mutagenesis. These mutations affect the axial and lateral contacts in the sickle fiber. The recombinant hemoglobin designated anti-sickling hemoglobin 1 (Hb AS1) contains the mutations beta 22 glutamic acid to alanine and beta 80 asparagine to lysine. Hb AS2 has the same beta 22 glutamic acid to alanine mutation combined with beta 87 threonine to glutamine. Human alpha- and beta AS-globin genes were separately fused downstream of beta-globin locus control region sequences and these constructs were coinjected into fertilized mouse eggs. Transgenic mouse lines that synthesize high levels of each anti-sickling hemoglobin were established and anti-sickling hemoglobins were purified from hemolysates and characterized. Both AS hemoglobins bind oxygen cooperatively and the oxygen affinities of these molecules are in the normal range. Delay time experiments demonstrate that Hb AS2 is a potent inhibitor of Hb S polymerization; therefore, locus control region beta AS2-globin gene constructs may be suitable for future gene therapy of sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
INGRAM, V. M. (1957) · Nature · doi:10.1038/180326a0 · Cited by 978
A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin
INGRAM, V. M. (1956) · Nature · doi:10.1038/178792a0 · Cited by 896
Hemoglobin S gelation and sickle cell disease
Eaton, W., & Hofrichter, J. (1987) · Blood · doi:10.1182/blood.v70.5.1245.1245 · Cited by 425
Nagel, R. L., Bookchin, R. M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W. A., Honig, G. R., Schilirò, G., Crookston, J. H., & Matsutomo, K. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.2.670 · Cited by 196
Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S
Dykes, G. W., Crepeau, R. H., & Edelstein, S. J. (1979) · Journal of Molecular Biology · doi:10.1016/0022-2836(79)90434-0 · Cited by 186
Cited by
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase
Chen, W. Y., Bailey, E. C., McCune, S. L., Dong, J.-Y., & Townes, T. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5798 · Cited by 256
Self-citationGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin
Levasseur, D. N., Ryan, T. M., Reilly, M. P., McCune, S. L., Asakura, T., & Townes, T. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402578200 · Cited by 67
Self-citationTakekoshi, K. J., Oh, Y. H., Westerman, K. W., London, I. M., & Leboulch, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3014 · Cited by 39
Metadata
- Authors
- McCune, S. L., Reilly, M. P., Chomo, M. J., Asakura, T., & Townes, T. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-10-11
- Volume
- 91
- Issue
- 21
- Pages
- 9852-9856
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2015478873
- Cited by
- 65
- References
- 5
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.